Sophia Antipolis, France.
 
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today provides an update on its revenues and cash position for the first nine months of 2014.
 
Michele Garufi, Chief Executive Officer of Nicox, commented: “In the third quarter of this year, we have achieved important progress in building our therapeutic ophthalmic pipeline, thanks to the positive pivotal phase 3 results for VESNEO and the recently completed acquisition of Aciex Therapeutics, Inc. Nicox now has two product candidates which have completed phase 3 trials and this increases our confidence in our future prospects as a competitive International Ophthalmic Group.”
 
To read the full press release please download the PDF